In today’s competitive global market, pharmaceutical companies cannot afford to waste time or resources on strategies that do not fit patient needs or generate scripts. Interconnectivity between all stakeholders and a 360° view of everything that…
Pharmaceutical manufacturers relying on the standard model for executing market access and field deployment strategies utilize resources inefficiently and redundantly. By integrating actions across operations, manufacturers can right size company resources, ensure affordability and increase speed…
Rare diseases are complex, and with limited research available, therapeutic options are often limited. Gene therapy, a growing area of clinical research, is showing great promise in treatment that may be life-altering for patients with many…
The need to develop a strong, comprehensive data-analytics strategy to support pharma and healthcare initiatives cannot be stated strongly enough. Data is unbiased; it can validate hypotheses or provide direction. But the primary goal is to…
Three Key Objectives Guide Program Development: Access, Affordability and Adherence Patients taking branded therapies to manage long-term health conditions are faced with a dizzying array of challenges, all of which can hinder access to medication, create…
In recent years, there has been increasing appetite among manufacturers — and growing capabilities among specialized channel-distribution service providers — to shorten the value chain. When drug manufacturers reflexively commit to a distribution model that is…
Due to rising cyber-attacks and the potential to cause harm to patients, medical facilities and hospitals, the U.S. Food and Drug Administration (FDA) has recently increased scrutiny of cyber controls in FDA premarket submissions of medical…
As rare diseases become an increasing area of global focus, pharmaceutical manufacturers are taking a closer look at how patient-reported outcomes (PROs) may be used to improve uptake in HTA evaluations. Although “rare” suggests not many…
“The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems” EVERSANA™ was the only data and analytic organization invited by a consortium of provider organizations and the NIH to…
Established brands do not require significant proactive investment or attention from commercial teams and generate revenue for biopharma companies to reinvest and improve healthcare value for patients, providers and payers. Established brands have seen a decrease…